Drug Pipeline

Lurbinectedin Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
21
Active Studies
12
Recruiting
6
Phase 3
10
Top Sponsors
6
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-06-12 NCT07328425
Clinical Study in Adult and Young Adult Patients With Advanced Desmoplastic Small Round…
Trial sites expanded: 1 -> 5 locations
2026-05-21 NCT06801834
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously…
Trial sites expanded: 205 -> 210 locations
2026-05-19 NCT07155174
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of…
Trial sites expanded: 34 -> 49 locations
2026-05-16 NCT06088290
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as…
overall status: "Recruiting" → "Active Not Recruiting"
2026-05-14 NCT05153239
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus…
Trial completed
2026-05-14 NCT07155174
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of…
Trial sites reduced: 42 -> 34 locations
New Trial Filings, Last 30 Days
First PostedTrialPhaseStatus
2026-06-11 NCT07640932 Lurbinectedin Plus Paclitaxel Versus Paclitaxel in Patients With Previously Treated Small… Phase 2 Not Yet Recruiting
Active Studies by Phase
Phase 3
6
Phase 2
9
Phase 1/2
5
Phase 1
1
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT06801834 Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously… Extensive Stage Small Cell Lung Cancer (ES-SCLC) Recruiting
NCT06203210 A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With… Small Cell Lung Cancer Recruiting
NCT05740566 Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung… Small Cell Lung Cancer (SCLC) Active, Not Recruiting
NCT07365241 A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706… Small Cell Lung Cancer Not Yet Recruiting
NCT06088290 Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as… Leiomyosarcoma Active, Not Recruiting
NCT05091567 A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With… Small-Cell Lung Cancer Active, Not Recruiting
Phase 2
NCT05578326 Study of Trilaciclib and Lurbinectidin Lung Cancer Recruiting
NCT05800587 Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer Lung Cancer Recruiting
NCT06228066 Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER) Small Cell Carcinoma of the Bladder Recruiting
NCT06497530 Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC Extensive-Stage Small Cell Lung Cancer Recruiting
NCT07155174 A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of… Small Cell Lung Cancer Recruiting
NCT07328425 Clinical Study in Adult and Young Adult Patients With Advanced Desmoplastic Small Round… Desmoplastic Small Round Cell Tumor Recruiting
NCT04607954 Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung… Platinum-Resistant Lung Small Cell Carcinoma Active, Not Recruiting
NCT07459634 A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants… Extensive-stage Small-cell Lung Cancer Not Yet Recruiting
NCT07640932 Lurbinectedin Plus Paclitaxel Versus Paclitaxel in Patients With Previously Treated Small… Carcinoma, Small Cell Lung Not Yet Recruiting
Phase 1/2
NCT05734066 Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With… Refractory Ewing Sarcoma Recruiting
NCT06681220 Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC Relapsed Small Cell Lung Cancer Recruiting
NCT05918640 Lurbinectedin in FET-Fused Tumors Ewing Sarcoma Recruiting
NCT04802174 Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and… SCLC Active, Not Recruiting
NCT05099666 Lurbinectedin + Doxorubicin In Leiomyosarcoma Advanced Soft-tissue Sarcoma Active, Not Recruiting
Phase 1
NCT05636111 Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in… Ovarian Cancer Recruiting
Sponsors Running Lurbinectedin Trials
Disease Areas
Get alerts when Lurbinectedin trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free